



ASX Announcement
20 March 2024

OPTISCAN RECEIVES R&D TAX INCENTIVE REBATE

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') is pleased to advise that the Company has received its R&D Tax Incentive rebate for the 2022/2023 financial year amounting to \$672,320. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

Optiscan CEO and Managing Director, Dr Camile Farah, said, "The Company has continued to undertake significant research and development as it prepares its devices for clinical deployment. The funds made available through the R&D Tax Incentive will be used to support ongoing innovations to the Company's digital pathology platform as it expands its product portfolio and clinical indications."

The R&D receivable amount to 30 June 2023 was accounted for in the Statement of Financial Position as at 31 December 2023.

This announcement has been authorised for release by the Board of Optiscan.

– ends –

For investor queries, please contact:

Dr. Camile Farah
Chief Executive Officer & Managing Director
Optiscan Imaging Ltd
E: ceo@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology

P: (61 3) 9538 3333
A: 16 Miles St, Mulgrave VIC 3170, Australia
W: www.optiscan.com

images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com